COX, LOX & Prostaglandins: The Biochemistry of Inflammation

Why the Biochemistry of Inflammation Matters

When you take an aspirin for a headache or an ibuprofen for joint pain, you are intervening in one of the most fundamental biochemical pathways in human biology — the eicosanoid cascade. NSAIDs are among the most widely used drugs in the world, yet most people — and many clinicians — have only a surface-level understanding of what they actually do and why selective inhibition matters profoundly for long-term health.

Understanding the COX and LOX pathways is not merely academic. It explains:

• Why NSAIDs cause gastrointestinal damage and cardiovascular risk
• Why selective COX-2 inhibitors (like celecoxib) increase heart attack risk
• Why targeting only one arm of the eicosanoid cascade often worsens the other
• Why dietary fatty acid composition is one of the most powerful levers for modulating inflammation
• How natural compounds (curcumin, boswellia, omega-3s) produce broad anti-inflammatory effects with superior safety profiles

Eicosanoids: The Molecular Currency of Inflammation

Eicosanoids are a superfamily of bioactive lipid mediators derived from 20-carbon polyunsaturated fatty acids (PUFAs). They include prostaglandins, thromboxanes, leukotrienes, lipoxins, and the omega-3-derived resolvins and protectins. They function as local hormones — synthesized on demand, acting in the immediate cellular microenvironment, and rapidly inactivated.

Eicosanoids regulate virtually every aspect of the inflammatory response: vasodilation and vasoconstriction, platelet aggregation, bronchodilation and bronchoconstriction, neutrophil recruitment, pain sensitization, fever, and — critically — inflammation resolution.

The two primary enzyme systems that generate eicosanoids from membrane fatty acids are:

• Cyclooxygenase (COX-1 and COX-2) — producing prostaglandins and thromboxanes
• Lipoxygenase (5-LOX, 12-LOX, 15-LOX) — producing leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids (HETEs)

Step 1: Membrane Phospholipid Liberation

The eicosanoid cascade begins with the liberation of arachidonic acid (AA) from the phospholipid bilayer of cell membranes. This is catalyzed by phospholipase A2 (PLA2), which is activated by:

• Cell membrane damage (trauma, infection, oxidative stress)
• Pro-inflammatory cytokines (TNF-α, IL-1β)
• Toll-like receptor (TLR) activation by PAMPs and DAMPs
• Calcium influx into cells

Arachidonic acid — an omega-6 fatty acid — is the primary substrate for pro-inflammatory eicosanoid synthesis. Its availability in cell membranes is directly determined by dietary omega-6 intake. Diets high in linoleic acid (vegetable oils, processed foods) increase membrane AA content and prime cells for amplified inflammatory responses.

EPA (eicosapentaenoic acid, from omega-3s) competes with AA for the same enzyme systems — producing eicosanoids with dramatically reduced inflammatory potency, or pro-resolving mediators. This is the molecular basis for the anti-inflammatory effects of omega-3 fatty acids.

The COX Pathway: Prostaglandins & Thromboxanes

COX-1 vs. COX-2: Critical Distinctions

Cyclooxygenase exists in two isoforms with distinct expression patterns and physiological roles:

COX-1 (Constitutive)

COX-1 is expressed constitutively — constantly present — in virtually all tissues. Its primary roles are housekeeping and cytoprotection:

• Gastric mucosa: COX-1-derived PGE2 and PGI2 stimulate mucus secretion and bicarbonate production, maintaining the protective gastric mucosal barrier
• Platelets: COX-1-derived thromboxane A2 (TXA2) promotes platelet aggregation and vascular homeostasis
• Kidneys: COX-1-derived prostaglandins maintain renal blood flow, particularly under conditions of volume depletion
• Vascular endothelium: COX-1-derived prostacyclin (PGI2) inhibits platelet aggregation and promotes vasodilation — balancing TXA2

COX-2 (Inducible)

COX-2 is largely absent in healthy tissue but is rapidly induced by inflammatory stimuli — cytokines (IL-1β, TNF-α), LPS, growth factors, and NF-κB activation. COX-2 is the primary driver of inflammatory prostaglandin production:

• Generates PGE2 at sites of inflammation — the primary prostaglandin mediating pain sensitization, vasodilation, fever, and edema
• Expressed in macrophages, synoviocytes, endothelial cells, neurons, and cancer cells
• Also expressed constitutively in the brain, kidneys, and reproductive tissues — serving physiological roles beyond inflammation

The Prostaglandins: What They Do

Once arachidonic acid is processed by COX enzymes, it forms PGH2 — an unstable intermediate that is rapidly converted by tissue-specific synthases into distinct prostaglandins with different, sometimes opposing, effects:

• PGE2 (Prostaglandin E2): The master pro-inflammatory prostaglandin. Sensitizes peripheral nociceptors (lowering pain threshold), causes vasodilation and edema, elevates hypothalamic set point (fever), suppresses T cell function, and promotes tumor microenvironment formation. Acts via four receptor subtypes (EP1–EP4) with context-dependent effects.
• PGI2 (Prostacyclin): Primarily vasodilatory and anti-aggregatory. Produced by vascular endothelium; balances TXA2. This is why selective COX-2 inhibition is prothrombotic — it suppresses COX-2-derived PGI2 in endothelial cells while leaving COX-1-derived TXA2 in platelets intact, tipping the balance toward clotting and cardiovascular risk.
• TXA2 (Thromboxane A2): Potent platelet aggregator and vasoconstrictor. Produced primarily in platelets via COX-1. Aspirin’s cardioprotective effect comes from irreversibly acetylating COX-1 in platelets — suppressing TXA2 for the platelet’s 10-day lifespan.
• PGD2: Involved in allergic inflammation and sleep regulation; promotes bronchoconstriction and mast cell degranulation in allergic responses.
• PGF2α: Promotes uterine contraction, bronchoconstriction, and vasoconstriction.

Why Non-Selective NSAIDs Damage the Gut

Traditional NSAIDs (ibuprofen, naproxen, diclofenac) inhibit both COX-1 and COX-2 non-selectively. Blocking COX-1 in the gastric mucosa eliminates the cytoprotective PGE2 and PGI2 that maintain mucosal integrity. The result: reduced mucus secretion, reduced bicarbonate buffering, and impaired mucosal blood flow — creating conditions for gastric erosion and ulceration. Approximately 15–30% of regular NSAID users develop peptic ulcers; GI complications from NSAIDs cause an estimated 100,000 hospitalizations per year in the US.

The LOX Pathway: Leukotrienes & Lipoxins

5-LOX: The Pro-Inflammatory Arm

5-Lipoxygenase (5-LOX) converts arachidonic acid — with the assistance of its activating protein FLAP (5-lipoxygenase activating protein) — into 5-HPETE and then leukotriene A4 (LTA4). LTA4 is the unstable precursor for two major leukotriene families:

Leukotriene B4 (LTB4)

LTB4 is one of the most potent chemoattractants in biology — a powerful recruiter of neutrophils and macrophages to sites of inflammation. It also:

• Activates neutrophil oxidative burst and degranulation
• Promotes T cell and NK cell activation
• Drives chronic inflammatory conditions: psoriasis, inflammatory bowel disease, atherosclerosis, and rheumatoid arthritis
• Activates PPARα — linking lipid metabolism and inflammation

Cysteinyl Leukotrienes (LTC4, LTD4, LTE4)

The cysteinyl leukotrienes (CysLTs) are the most potent bronchoconstrictors known — up to 1,000 times more potent than histamine on a molar basis. They are the primary mediators of:

• Asthma (airway bronchoconstriction, mucus hypersecretion, airway edema)
• Allergic rhinitis
• Exercise-induced bronchoconstriction
• Aspirin-exacerbated respiratory disease (AERD) — where COX inhibition shunts AA toward 5-LOX, dramatically increasing CysLT production

Leukotriene receptor antagonists (montelukast/Singulair, zafirlukast) block CysLT receptors and are standard therapy for asthma and allergic rhinitis.

12-LOX and 15-LOX: The Resolving Arms

Not all LOX activity is pro-inflammatory. 15-LOX — acting on arachidonic acid and omega-3 fatty acids — generates lipoxins, which are the body’s endogenous “stop signals” for acute inflammation:

• Lipoxin A4 (LXA4): Inhibits neutrophil recruitment, promotes macrophage clearance of apoptotic cells (efferocytosis), and reduces vascular permeability — actively terminating the inflammatory response
• 15-epi-LXA4 (aspirin-triggered lipoxin): Aspirin acetylates COX-2, changing its product specificity from PGE2 to 15-HETE — which 5-LOX then converts to aspirin-triggered lipoxins. This is one mechanism by which low-dose aspirin has anti-inflammatory effects beyond just TXA2 suppression.

EPA and DHA from omega-3 fatty acids feed 15-LOX and 5-LOX to produce resolvins (from EPA: E-series; from DHA: D-series) and protectins/neuroprotectins (from DHA) — the most potent pro-resolving mediators known, active at picomolar concentrations.

The COX-LOX Shunting Problem

A critical — and underappreciated — pharmacological phenomenon: when one pathway is blocked, arachidonic acid is shunted into the other. This has clinically significant consequences:

• NSAIDs and aspirin-exacerbated respiratory disease (AERD): COX inhibition diverts AA to 5-LOX — dramatically increasing cysteinyl leukotriene production. In AERD patients (approximately 10–20% of asthmatics), this causes severe bronchospasm. NSAIDs are contraindicated in this population.
• COX-2 selective inhibitors and cardiovascular risk: Selective COX-2 inhibition reduces PGI2 (antithrombotic) while leaving TXA2 (prothrombotic) intact — increasing thrombotic cardiovascular events. Rofecoxib (Vioxx) was withdrawn from the market in 2004 after demonstrating a 2-fold increase in MI risk.
• Omega-6 dominance: When cellular AA is high (high omega-6 diet), blocking COX ensures that 5-LOX receives a larger substrate pool — potentially increasing leukotriene production. This is why dietary omega-6 reduction is important alongside any anti-inflammatory pharmacological strategy.

Natural Dual-Pathway Inhibitors

Several natural compounds inhibit both COX and LOX pathways simultaneously — avoiding the shunting problem — while providing additional anti-inflammatory mechanisms:

Boswellia serrata (Frankincense)

Boswellic acids — particularly AKBA (acetyl-11-keto-β-boswellic acid) — are potent, selective 5-LOX inhibitors. Unlike NSAIDs, boswellia specifically targets the leukotriene arm of the eicosanoid cascade without inhibiting COX or causing gastric damage. AKBA also inhibits FLAP (5-LOX activating protein) and NF-κB. Clinical evidence supports its use in:

• Osteoarthritis (comparable to NSAIDs in pain reduction with superior tolerability)
• Inflammatory bowel disease (Crohn’s, ulcerative colitis)
• Asthma (leukotriene-mediated bronchoconstriction)
• Brain tumor-associated edema (reduces PGE2 and leukotriene-driven neuroinflammation)

Curcumin

Curcumin inhibits both COX-2 (transcriptionally, via NF-κB suppression) and 5-LOX (directly). It also inhibits PLA2 — reducing arachidonic acid liberation upstream of both pathways. Additional mechanisms include: Nrf2 activation (antioxidant response), NLRP3 inflammasome suppression, and CGRP reduction. Requires high-bioavailability formulations for clinical effect.

Omega-3 Fatty Acids (EPA & DHA)

EPA and DHA work at the substrate level — replacing AA in cell membranes and competing for COX and LOX enzymes. When EPA is processed by COX-2, it produces 3-series prostaglandins (PGE3) — which are significantly less inflammatory than the 2-series (PGE2). When processed by 5-LOX, EPA produces 5-series leukotrienes (LTB5) — which have <10% the chemoattractant potency of LTB4. EPA and DHA also directly generate resolvins, protectins, and maresins via 15-LOX and cytochrome P450 pathways — actively driving inflammation resolution.

Quercetin

Quercetin inhibits both 5-LOX and COX-2, stabilizes mast cells (reducing PLA2 activation), and inhibits histamine release. It also acts as an NLRP3 inflammasome inhibitor and NF-κB suppressor — providing broad upstream anti-inflammatory activity.

Resveratrol

Inhibits COX-1 and COX-2 (at higher concentrations), activates SIRT1 (which deacetylates and inhibits NF-κB), and reduces PGE2 production in inflammatory cells. Also activates Nrf2 and has significant effects on NLRP3 inflammasome activity.

Dietary Modulation of the Eicosanoid Cascade

The composition of cell membrane fatty acids — which determines the substrate available for COX and LOX enzymes — is directly controlled by diet. This makes dietary intervention one of the most powerful and sustainable strategies for modulating eicosanoid balance:

• Reduce omega-6 (linoleic acid): Eliminate industrial seed oils (soybean, corn, sunflower, safflower, canola). These are the primary source of excess dietary omega-6 in the Western diet and directly increase membrane AA content.
• Increase omega-3 (EPA & DHA): Fatty fish (salmon, sardines, mackerel, herring), fish oil supplementation (2–4 g/day EPA+DHA). Replaces AA in membranes and shifts eicosanoid production toward less inflammatory and pro-resolving species.
• Reduce arachidonic acid intake: AA is found primarily in factory-farmed meat and eggs. Pasture-raised and grass-fed animal products have more favorable omega-3/omega-6 ratios.
• Polyphenol-rich diet: Colorful vegetables, berries, olive oil, green tea, and spices (turmeric, ginger) provide natural COX/LOX modulators and reduce NF-κB-driven PLA2 activation.

Summary: COX vs. LOX at a Glance

Related Articles

• The Inflammatory Cascade: Acute vs. Chronic Inflammation
• Omega-3s, EPA/DHA & the Inflammation Connection
• Curcumin: Nature’s Most Powerful Anti-Inflammatory Compound
• Curcumin & Turmeric: Inflammation, Cancer Defense & Whole-Body Healing
• Pain & Inflammation Hub

This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.